vs
i3 Verticals, Inc.（IIIV）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是i3 Verticals, Inc.的1.2倍（$65.1M vs $52.7M），MESA LABORATORIES INC净利率更高（5.6% vs 0.9%，领先4.7%），MESA LABORATORIES INC同比增速更快（3.6% vs -14.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $13.8M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -4.7%）
Prusa i3是捷克Prusa Research公司生产的熔融沉积成型3D打印机系列，以Original Prusa i3为注册商标推出，同时也是RepRap项目的组成部分。2016年该系列就被评为全球使用率最高的3D打印机，最早由Josef Průša在2012年完成设计，2015年正式推出商用套件版本，目前最新型号同时提供散件套件和原厂组装版本，具备性价比高、易操作的优势。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
IIIV vs MLAB — 直观对比
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $52.7M | $65.1M |
| 净利润 | $484.0K | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 3.1% | 12.2% |
| 净利率 | 0.9% | 5.6% |
| 营收同比 | -14.6% | 3.6% |
| 净利润同比 | -76.5% | 316.6% |
| 每股收益（稀释后） | $0.02 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $52.7M | $65.1M | ||
| Q3 25 | $46.0M | $60.7M | ||
| Q2 25 | $51.9M | $59.5M | ||
| Q1 25 | $63.1M | $62.1M | ||
| Q4 24 | $52.2M | $62.8M | ||
| Q3 24 | $32.0M | $57.8M | ||
| Q2 24 | $46.2M | $58.2M | ||
| Q1 24 | $58.0M | $58.9M |
| Q4 25 | $484.0K | $3.6M | ||
| Q3 25 | $3.1M | $2.5M | ||
| Q2 25 | $12.9M | $4.7M | ||
| Q1 25 | $-154.0K | $-7.1M | ||
| Q4 24 | $2.1M | $-1.7M | ||
| Q3 24 | $117.9M | $3.4M | ||
| Q2 24 | $-7.5M | $3.4M | ||
| Q1 24 | $1.9M | $-254.6M |
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
| Q4 25 | 3.1% | 12.2% | ||
| Q3 25 | 3.2% | 7.8% | ||
| Q2 25 | -9.3% | 5.1% | ||
| Q1 25 | 8.0% | 2.4% | ||
| Q4 24 | 3.9% | 9.2% | ||
| Q3 24 | 10.6% | 6.1% | ||
| Q2 24 | -2.8% | 9.6% | ||
| Q1 24 | 3.4% | -460.6% |
| Q4 25 | 0.9% | 5.6% | ||
| Q3 25 | 6.7% | 4.1% | ||
| Q2 25 | 24.8% | 8.0% | ||
| Q1 25 | -0.2% | -11.4% | ||
| Q4 24 | 3.9% | -2.7% | ||
| Q3 24 | 368.2% | 5.9% | ||
| Q2 24 | -16.3% | 5.8% | ||
| Q1 24 | 3.2% | -432.2% |
| Q4 25 | $0.02 | $0.65 | ||
| Q3 25 | $0.14 | $0.45 | ||
| Q2 25 | $0.50 | $0.85 | ||
| Q1 25 | $0.00 | $-1.30 | ||
| Q4 24 | $0.08 | $-0.31 | ||
| Q3 24 | $4.93 | $0.63 | ||
| Q2 24 | $-0.32 | $0.62 | ||
| Q1 24 | $0.08 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.5M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $358.5M | $186.7M |
| 总资产 | $595.9M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
| Q4 25 | $37.5M | $29.0M | ||
| Q3 25 | $66.7M | $20.4M | ||
| Q2 25 | $55.5M | $21.3M | ||
| Q1 25 | $7.7M | $27.3M | ||
| Q4 24 | $85.6M | $27.3M | ||
| Q3 24 | $86.5M | $24.3M | ||
| Q2 24 | $9.7M | $28.5M | ||
| Q1 24 | $3.1M | $28.2M |
| Q4 25 | — | $68.4M | ||
| Q3 25 | $0 | $69.4M | ||
| Q2 25 | $0 | $70.3M | ||
| Q1 25 | $12.0M | $71.3M | ||
| Q4 24 | $26.2M | $72.2M | ||
| Q3 24 | $26.2M | $73.1M | ||
| Q2 24 | $374.1M | $74.1M | ||
| Q1 24 | $369.6M | — |
| Q4 25 | $358.5M | $186.7M | ||
| Q3 25 | $389.6M | $178.5M | ||
| Q2 25 | $383.3M | $172.5M | ||
| Q1 25 | $385.2M | $159.8M | ||
| Q4 24 | $375.0M | $155.2M | ||
| Q3 24 | $379.7M | $161.5M | ||
| Q2 24 | $249.7M | $150.7M | ||
| Q1 24 | $249.3M | $145.4M |
| Q4 25 | $595.9M | $434.8M | ||
| Q3 25 | $638.4M | $430.4M | ||
| Q2 25 | $623.3M | $435.7M | ||
| Q1 25 | $646.4M | $433.3M | ||
| Q4 24 | $726.2M | $433.3M | ||
| Q3 24 | $730.7M | $454.1M | ||
| Q2 24 | $861.7M | $440.4M | ||
| Q1 24 | $625.8M | $446.8M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | 0.00× | 0.39× | ||
| Q2 25 | 0.00× | 0.41× | ||
| Q1 25 | 0.03× | 0.45× | ||
| Q4 24 | 0.07× | 0.47× | ||
| Q3 24 | 0.07× | 0.45× | ||
| Q2 24 | 1.50× | 0.49× | ||
| Q1 24 | 1.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.1M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $13.8M | $18.0M |
| 自由现金流率自由现金流/营收 | 26.2% | 27.7% |
| 资本支出强度资本支出/营收 | 0.6% | 1.1% |
| 现金转化率经营现金流/净利润 | 29.18× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $6.5M | $37.9M |
8季度趋势，按日历期对齐
| Q4 25 | $14.1M | $18.8M | ||
| Q3 25 | $14.0M | $8.2M | ||
| Q2 25 | $7.4M | $1.9M | ||
| Q1 25 | $-27.1M | $12.7M | ||
| Q4 24 | $11.5M | $18.1M | ||
| Q3 24 | $15.1M | $5.3M | ||
| Q2 24 | $8.1M | $10.7M | ||
| Q1 24 | $10.7M | $12.9M |
| Q4 25 | $13.8M | $18.0M | ||
| Q3 25 | $13.5M | $7.1M | ||
| Q2 25 | $6.8M | $884.0K | ||
| Q1 25 | $-27.6M | $11.9M | ||
| Q4 24 | $11.0M | $17.3M | ||
| Q3 24 | $14.6M | $3.5M | ||
| Q2 24 | $7.2M | $9.9M | ||
| Q1 24 | $9.9M | $12.3M |
| Q4 25 | 26.2% | 27.7% | ||
| Q3 25 | 29.5% | 11.7% | ||
| Q2 25 | 13.1% | 1.5% | ||
| Q1 25 | -43.8% | 19.2% | ||
| Q4 24 | 21.1% | 27.6% | ||
| Q3 24 | 45.6% | 6.0% | ||
| Q2 24 | 15.6% | 16.9% | ||
| Q1 24 | 17.1% | 21.0% |
| Q4 25 | 0.6% | 1.1% | ||
| Q3 25 | 0.9% | 1.8% | ||
| Q2 25 | 1.0% | 1.7% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 0.9% | 1.3% | ||
| Q3 24 | 1.7% | 3.1% | ||
| Q2 24 | 1.9% | 1.5% | ||
| Q1 24 | 1.4% | 0.9% |
| Q4 25 | 29.18× | 5.17× | ||
| Q3 25 | 4.52× | 3.32× | ||
| Q2 25 | 0.57× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.59× | — | ||
| Q3 24 | 0.13× | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | 5.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IIIV
| License And Service | $35.7M | 68% |
| Proprietary Payments Revenue | $14.5M | 27% |
| Other Revenue | $2.5M | 5% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
